For example, detected through next-generation sequencing, the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like, also known as APOBEC, has been reported to predict the efficacy of immunotherapy (70), not only in NSCLC but also in pan-cancer analysis (71). This evidence concerns the gene APOB and non-small cell lung carcinoma.